Dr. Shah on the Current State of CAR T-Cell Therapy in Myeloma

Video

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the current state of CAR T-cell therapy in multiple myeloma.

Nina Shah, MD, associate professor, Department of Medicine, University of California, San Francisco Helen Diller Comprehensive Cancer Center, discusses the current state of chimeric antigen receptor (CAR) T-cell therapy in multiple myeloma.

Right now, most of the literature regarding CAR T-cell therapy is preliminary, Shah says, and the information available has only been presented at large oncology conferences. Data presented at the 2018 ASCO Annual Meeting showed that the CAR T-cell therapy bb2121 had a median progression-free survival (PFS) of 11.8 months and a median duration of response of 10.8 months for patients with relapsed/refractory heavily pretreated myeloma. Although, the median PFS for patients who achieved minimal residual disease negativity was over 17 months.

Shah says that these data demonstrate areas that can be improved. For example, the timing of CAR T-cell therapy could be earlier, so patients do not need to undergo 7 lines of therapy first. It could also be combined with different agents. Preclinical data have shown that CAR T cells in combination with immunomodulatory agents may make the T cells last longer.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.